I think one reason that Leo chose Mary Crowley is their groundbreaking research in cancer pathways. They certainly have the technology and expertise to determine K's MOA.
"MOLECULAR DATA ANALYSIS: BLOCKING SPECIFIC PATHWAYS
There are eight hallmark biological capabilities necessary for cancer development and persistence: (1) sustained proliferation, (2) evasion of growth suppressors, (3) death resistance, (4) replicate immortality, (5) angiogenesis, (6) invasion ± metastability, (7) reprogrammed energy metabolism, and (
immune evasion. These capabilities support one or more of three core processes, i.e., cell survival, cell fate and genome maintenance. These core processes are sub served by one or more of 12 signaling pathways.
UNDERSTANDING CANCER PATHWAYS
Insofar as a number of different genes/proteins can have rate limiting effects in a dominant signaling pathway, systems analysis can allow optimization of limited target pathway disruption. Further, given the cross-talk between pathways and that the robustness of the cancer network involves alternative and/or compensatory secondary pathway utilization, it is likely that more than one pathway needs to be targeted. For example, in non-small-cell lung cancer with an EGFR inhibitor sensitizing L858R mutation in exon 21, effective targeted therapy can be bypassed by upregulation of the cMet receptor and its downstream pathway. Mary Crowley has continued to offer a number of protocols with multiple node targeting—a major step in the development of Personalized Medicine."
https://www.marycrowley.org/groundbreaking-re...-pathways/
"MOLECULAR DATA ANALYSIS: BLOCKING SPECIFIC PATHWAYS
There are eight hallmark biological capabilities necessary for cancer development and persistence: (1) sustained proliferation, (2) evasion of growth suppressors, (3) death resistance, (4) replicate immortality, (5) angiogenesis, (6) invasion ± metastability, (7) reprogrammed energy metabolism, and (
immune evasion. These capabilities support one or more of three core processes, i.e., cell survival, cell fate and genome maintenance. These core processes are sub served by one or more of 12 signaling pathways. UNDERSTANDING CANCER PATHWAYS
Insofar as a number of different genes/proteins can have rate limiting effects in a dominant signaling pathway, systems analysis can allow optimization of limited target pathway disruption. Further, given the cross-talk between pathways and that the robustness of the cancer network involves alternative and/or compensatory secondary pathway utilization, it is likely that more than one pathway needs to be targeted. For example, in non-small-cell lung cancer with an EGFR inhibitor sensitizing L858R mutation in exon 21, effective targeted therapy can be bypassed by upregulation of the cMet receptor and its downstream pathway. Mary Crowley has continued to offer a number of protocols with multiple node targeting—a major step in the development of Personalized Medicine."
https://www.marycrowley.org/groundbreaking-re...-pathways/
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
